Clinical Context
A typical patient is a pediatric or adult with mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome) who requires regular enzyme replacement therapy with galsulfase. The patient arrives to an outpatient infusion center or hospital infusion clinic for scheduled intravenous administration. Verification steps include confirming the prescription for J1458 (galsulfase, 1 mg), recent weight-based dose calculation, current labs (renal and hepatic function), and documentation of prior infusion tolerance. Nursing prepares the dose under aseptic technique, inspects the product for particulate matter, and administers via peripheral or central IV access over the manufacturer-recommended infusion time with vital sign monitoring and emergency medications available. Typical workflow elements: insurance eligibility and prior authorization confirmation, medication reconciliation, dose verification by pharmacist, informed consent for infusion risks, administration with continuous monitoring for infusion-related reactions, documentation of lot number and units billed as J1458 per milligram, and post-infusion observation prior to discharge to home or routine follow-up visits.